Contact PI/Project LeaderWINDSOR, LILIANE CAMBRAIA Other PIs
Awardee OrganizationUNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN
Description
Abstract Text
Project Summary
COVID-19 has impacted the health and social fabric of individuals and families living across the United States;
and it has disproportionately affected people living in urban communities with co-morbidities, those working in high-
risk settings, refusing or unable to adhere to CDC guidelines, and more. Social determinants of health (SDH), such
as stigma, racial discrimination, xenophobia, incarceration, and poverty have been associated with increased
exposure to COVID-19 and increased deaths. Marginalized communities, defined as low-income and racial/ethnic
minority neighborhoods, where residents experience increased barriers (e.g., inadequate housing, high-risk jobs)
to prevention and treatment, bear disproportionately higher rates of co-morbidities associated with more severe
cases of COVID-19. While effective and potent vaccines are becoming more available, it will take time to reach
herd immunity and it is unclear how long newly-developed vaccines provide protection and how effective they are
against emerging variants. Therefore, prevention methods recommended by the Centers for Disease Control
(CDC) – i.e., testing, hand-washing, social distancing, contact tracing, vaccination, and quarantine -- are essential
to reduce the rates of COVID-19 in marginalized communities. Research about COVID-19 testing and vaccine
uptake in these communities must occur in real time and it must account for the fast-changing landscape of the
pandemic, including the impact of vaccine availability on testing uptake. Two cost-effective, evidence-based, and
culturally appropriate interventions have been effective in engaging people in HIV prevention and treatment – these
can be adapted and tested to help address COVID-19 prevention needs. Specifically, Navigation Services (NS)
have shown to increase HIV testing and adherence to treatment while addressing structural barriers that deter
treatment engagement in high-risk communities; and Brief Counseling (BC) has shown to increase HIV treatment
engagement. This study uses a Sequential, Multiple Assignment Randomized Trial (SMART) with 1,218 COVID-
19 medically/socially vulnerable people. Guided by the COVID-19 Continuum of Prevention, Care, and Treatment,
analysis will explore factors associated with testing and adherence to CDC COVID-19 prevention and treatment
recommendations. The study aims include: To examine the effectiveness of an adaptive intervention to increase
COVID-19 testing and adherence to CDC-recommendations of preventive behaviors – social distancing, hand-
washing, inoculation, mask-wearing, vaccination- on comparable but distinct samples. We will control for baseline,
time, demographics and COVID risk; (2) To examine the immediate and medium-term impact of the adaptive
intervention on COVID testing and adherence to recommendations by collecting follow-up data at 2,5,12 and 24
weeks post baseline. Implementation aim: To collect intervention implementation data (context, cost, barriers,
lessons learned) and develop implementation materials (facilitator training, intervention manual, treatment fidelity
measure). This study has
Public Health Relevance Statement
Project Narrative
Little is known about the acceptability of COVID-19 testing in low-income and racial/ethnic minority
neighborhoods, where residents experience increased barriers to prevention and treatment (e.g., unstable
housing, higher risk jobs). In this hybrid effectiveness/ implementation study, community members and
researchers will work together as partners with a community-based organization in Illinois and one in New
Jersey to test an intervention to increase COVID-19 testing and adherence to CDC COVID-19treatment and
prevention recommendations.
NIH Spending Category
No NIH Spending Category available.
Project Terms
AIDS preventionAddressAdherenceAffectAreaBehaviorBehavioralBlack raceCOVID testingCOVID-19COVID-19 preventionCOVID-19 testCOVID-19 testingCOVID-19treatmentCOVID-19 vaccineCaringCenters for Disease Control and Prevention (U.S.)Cessation of lifeCommunitiesContact TracingCounselingCountyDataEducational InterventionEffectivenessFamilyFollow-Up StudiesGenderGrantGuidelinesHIVHandwashingHealthHealth Services AccessibilityHerd ImmunityHousingHuman immunodeficiency virus testIllinoisImprisonmentIndividualInterventionIntervention StudiesLatinxLow incomeManualsMasksMeasuresMedicalMethodsNeighborhoodsNew JerseyOccupationsPamphletsParticipantPersonsPopulationPovertyPreventionPreventiveQuarantineRandomizedRecommendationRecording of previous eventsReportingResearchResearch PersonnelRiskSARS-CoV-2 exposureSARS-CoV-2 infectionSARS-CoV-2 variantSamplingSequential Multiple Assignment Randomized TrialServicesSocial BehaviorSocial DistanceSocial Health ServicesSymptomsTestingTextilesTimeUnited StatesUrban CommunityUrsidae FamilyVaccinationVaccinesVariantVulnerable PopulationsWomanWorkadaptive interventionbasebooster vaccinecommunity based participatory researchcomorbiditycoronavirus diseasecostcost effectivedemographicseffectiveness implementation studyethnic minorityevidence baseexperiencefollow-uphigh riskhousing instabilityimplementation interventionmarginalized communitymedical vulnerabilitymembermenmultiphase optimization strategypandemic diseasepublic health relevanceracial and ethnicracial discriminationrecruitsocialsocial health determinantssocial stigmasocial vulnerabilitysocioeconomicstesting accesstesting uptakevaccine acceptancevaccine accessvaccine development
National Institute of Allergy and Infectious Diseases
CFDA Code
855
DUNS Number
041544081
UEI
Y8CWNJRCNN91
Project Start Date
12-January-2022
Project End Date
31-December-2023
Budget Start Date
12-January-2022
Budget End Date
31-December-2022
Project Funding Information for 2022
Total Funding
$975,705
Direct Costs
$849,261
Indirect Costs
$126,444
Year
Funding IC
FY Total Cost by IC
2022
NIH Office of the Director
$975,705
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 1U01AI169469-01
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1U01AI169469-01
Patents
No Patents information available for 1U01AI169469-01
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1U01AI169469-01
Clinical Studies
No Clinical Studies information available for 1U01AI169469-01
News and More
Related News Releases
No news release information available for 1U01AI169469-01
History
No Historical information available for 1U01AI169469-01
Similar Projects
No Similar Projects information available for 1U01AI169469-01